Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

705 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. English DP, et al. Among authors: hui p. Cancer Med. 2014 Oct;3(5):1256-65. doi: 10.1002/cam4.274. Epub 2014 Jun 2. Cancer Med. 2014. PMID: 24890382 Free PMC article.
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. El-Sahwi K, et al. Among authors: hui p. Br J Cancer. 2010 Jan 5;102(1):134-43. doi: 10.1038/sj.bjc.6605448. Epub 2009 Nov 17. Br J Cancer. 2010. PMID: 19920829 Free PMC article.
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. El-Sahwi K, et al. Among authors: hui p. Mol Cancer Ther. 2010 Jan;9(1):57-66. doi: 10.1158/1535-7163.MCT-09-0675. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053761 Free PMC article.
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience.
Richter CE, Hui P, Buza N, Silasi DA, Azodi M, Santin AD, Schwartz PE, Rutherford TJ. Richter CE, et al. Among authors: hui p. J Clin Pathol. 2010 Jun;63(6):544-7. doi: 10.1136/jcp.2010.077446. Epub 2010 Apr 23. J Clin Pathol. 2010. PMID: 20418225
MicroRNA signatures differentiate uterine cancer tumor subtypes.
Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. Ratner ES, et al. Among authors: hui p. Gynecol Oncol. 2010 Sep;118(3):251-7. doi: 10.1016/j.ygyno.2010.05.010. Epub 2010 Jun 9. Gynecol Oncol. 2010. PMID: 20542546 Free PMC article.
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. Ratner E, et al. Among authors: hui p. Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647319 Free PMC article.
705 results